Enrofloxacin是一种氟喹诺酮类抗生素，具有广谱抗菌活性，对主要病原菌具有较高的杀菌活性。
Cas No.:93106-60-6
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Enrofloxacin is a fluoroquinolone antibiotic with a broad antibacterial spectrum and high bactericidal activity against major pathogenic bacteria [1]. Enrofloxacin binds to the DNA-topoisomerase complex at the cleavage–ligation site, leading to conformational changes in the enzyme and inhibiting DNA replication through inefficient DNA ligation [2]. Enrofloxacin has been used to control bacterial infections of the mastitis, respiratory, and gastrointestinal tracts in cattle[3].
In vitro, Enrofloxacin treatment (40µg/ml) for 72 hours significantly increased the γH2Ax level in Abrams cells and led to a significant decrease in cell viability[4]. Treatment with 200µg/ml Enrofloxacin for 4 days induced the characteristic of DNA fragmentation and the condensation of apoptotic cell nuclei in canine tendon cells and chondrocytes[5]. Treatment with 200µg/ml Enrofloxacin for 24 hours induced the release of lactate dehydrogenase (LDH) and an increase in reactive oxygen species (ROS) levels in L8824 cells, disrupting mitochondrial membrane potential and promoting cell death[6].
In vivo, Enrofloxacin treatment via oral administration at a dose of 10mg/kg every 12 hours for 7 days significantly reduced lung inflammation in mice after cerebral middle artery occlusion (MCAo), increased the survival rate of mice, and prevented weight loss[7]. Oral administration of water containing 0.27mg/ml Enrofloxacin daily for 2 weeks significantly alleviated the symptoms of contact sensitivity (CS) in mice, altered the composition of the intestinal flora, and promoted anti-inflammatory responses[8].
References:
[1] Lopez-Cadenas C, Sierra-Vega M, Garcia-Vieitez J J, et al. Enrofloxacin: pharmacokinetics and metabolism in domestic animal species[J]. Current Drug Metabolism, 2013, 14(10): 1042-1058.
[2] Grabowski Ł, Gaffke L, Pierzynowska K, et al. Enrofloxacin—the ruthless killer of eukaryotic cells or the last hope in the fight against bacterial infections?[J]. International journal of molecular sciences, 2022, 23(7): 3648.
[3] Mitchell M A. Enrofloxacin[J]. Journal of Exotic Pet Medicine, 2006, 15(1): 66-69.
[4] York D, Withers S S, Watson K D, et al. Enrofloxacin enhances the effects of chemotherapy in canine osteosarcoma cells with mutant and wild‐type p53[J]. Veterinary and comparative oncology, 2017, 15(3): 1087-1100.
[5] Lim S, Hossain M A, Park J, et al. The effects of enrofloxacin on canine tendon cells and chondrocytes proliferation in vitro[J]. Veterinary research communications, 2008, 32(3): 243-253.
[6] Liu B, Cui Y, Brown P B, et al. Cytotoxic effects and apoptosis induction of enrofloxacin in hepatic cell line of grass carp (Ctenopharyngodon idellus)[J]. Fish & Shellfish Immunology, 2015, 47(2): 639-644.
[7] Hetze S, Engel O, Römer C, et al. Superiority of preventive antibiotic treatment compared with standard treatment of poststroke pneumonia in experimental stroke: a bed to bench approach[J]. Journal of Cerebral Blood Flow & Metabolism, 2013, 33(6): 846-854.
[8] Strzępa A, Majewska-Szczepanik M, Lobo F M, et al. Broad spectrum antibiotic enrofloxacin modulates contact sensitivity through gut microbiota in a murine model[J]. Journal of Allergy and Clinical Immunology, 2017, 140(1): 121-133. e3.
Enrofloxacin是一种氟喹诺酮类抗生素，具有广谱抗菌活性，对主要病原菌具有较高的杀菌活性[1]。Enrofloxacin在切割-连接位点与DNA-拓扑异构酶复合物结合，导致酶构象改变，并通过低效的DNA连接来抑制DNA复制[2]。Enrofloxacin已被用于控制牛的乳腺炎、呼吸道和胃肠道细菌感染[3]。
在体外，40µg/ml的Enrofloxacin处理Abrams细胞72小时，显著增加了γH2Ax水平，并导致细胞活力显著下降[4]。200µg/ml的Enrofloxacin处理犬肌腱细胞和软骨细胞4天，诱导了DNA片段化和凋亡细胞核浓缩的特征[5]。200µg/ml的Enrofloxacin处理L8824细胞24小时，诱导了乳酸脱氢酶（LDH）的释放和活性氧（ROS）水平的升高，破坏了线粒体膜电位并促进了细胞死亡[6]。
在体内，每12小时口服10mg/kg剂量的Enrofloxacin，连续7天，显著减轻了大脑中动脉闭塞（MCAo）后小鼠的肺部炎症，提高了小鼠的存活率，并防止了体重下降[7]。每日饮用含0.27mg/ml Enrofloxacin的水，持续2周，显著减轻了小鼠的接触敏感性（CS）症状，改变了肠道菌群的组成，并促进了抗炎反应[8]。
| Cell experiment [1]: | |
Cell lines | Canine tendon cells |
Preparation Method | Canine tendon cells were seeded onto 96-well flat-bottomed microculture plates at a density of 1×104 cells/well in 200μl of DMEM medium. The cells were allowed to adhere to the plates and were treated with various concentrations of Enrofloxacin (10, 50, 100, and 200μg/ml) for 4 days, and the cell proliferation was measured. |
Reaction Conditions | 10, 50, 100, and 200μg/ml; 4 days |
Applications | Enrofloxacin treatment significantly enhanced cell proliferation of canine tendon cells in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | Male C57Bl6/J mice |
Preparation Method | Male C57Bl6/J mice (11 weeks old) were housed in a room with controlled temperature (21-23°C), humidity (55-60%), and lighting (12h light/dark cycle) and were supplied with water. After anesthesia induction with isoflurane in a 1:2 mixture of oxygen/nitrous oxide, a ventral cervical midline incision was made, and a 12-mm silicon-coated nylon filament was introduced over the common carotid artery, further to the internal carotid artery, to occlude the origin of the middle cerebral artery. After an ischemia time of 60 minutes, the filament was removed for reperfusion. Body temperature was controlled throughout the procedure. Mice obtained Enrofloxacin (10mg/kg; p.o.) after waking from reperfusion anesthesia (ca. 1 hour after the operation) via feeding needle every 12 hours over a period of 7 days. The bacterial burden of lung and survival were measured. |
Dosage form | 10mg/kg; every 12 hours for 7 days; p.o. |
Applications | Enrofloxacin treatment alleviated the bacterial burden of the lung and improved survival in mice with MCAo. |
References: | |
| Cas No. | 93106-60-6 | SDF | |
| 别名 | 恩诺沙星; BAY Vp 2674; PD160788 | ||
| 化学名 | 1-cyclopropyl-7-(4-ethylpiperazin-1-yl)-6-fluoro-4-oxoquinoline-3-carboxylic acid | ||
| Canonical SMILES | CCN1CCN(CC1)C2=C(C=C3C(=C2)N(C=C(C3=O)C(=O)O)C4CC4)F | ||
| 分子式 | C19H22FN3O3 | 分子量 | 359.39 |
| 溶解度 | ≥ 15mg/mL in DMSO with gentle warming | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.7825 mL | 13.9125 mL | 27.8249 mL |
| 5 mM | 556.5 μL | 2.7825 mL | 5.565 mL |
| 10 mM | 278.2 μL | 1.3912 mL | 2.7825 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet